Momenta And Mylan Make Strides On Aflibercept
Partners Are Aiming For Market Entry In 2023
Having largely shelved the firms' global biosimilars collaboration that kicked off early in 2016, Momenta and Mylan are still working towards bringing a biosimilar to the Eylea blockbuster to the US, which currently has a market worth valued at more than $4.5bn.
